Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of an advanced/metastatic solid tumor * Confirmed presence of a KRASG12C mutation * Ineligible for an ongoing clinical trial of MRTX849 * No available or not eligible for standard of care treatment * Adequate organ function * CNS Metastases (within set parameters) are allowed * ECOG performance status of ≤ 2 Exclusion Criteria: * History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of MRTX849 treatment or result in inability to swallow * Prior therapy targeting a KRAS G12C mutation * Other active cancer